Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

@article{Farid2007CytochromeP3,
  title={Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.},
  author={Nagy A. Farid and Christopher D. Payne and David S. Small and Kenneth J. Winters and Charles S Ernest and John Brandt and Christelle Darstein and Joseph A. Jakubowski and Daniel E. Salazar},
  journal={Clinical pharmacology and therapeutics},
  year={2007},
  volume={81 5},
  pages={735-41}
}
Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R-138727) is formed primarily by cytochrome P450 (CYP) 3A and CYP2B6, with roles for CYP2C9 and CYP2C19. Clopidogrel's activation involves two sequential steps by CYP3A, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6. In a randomized crossover study, healthy subjects received a loading dose (LD) of prasugrel (60 mg) or clopidogrel (300 mg), followed by five daily maintenance doses… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 113 extracted citations

Similar Papers

Loading similar papers…